AI Article Synopsis
- The study investigates the knowledge, acceptance, motivators, and barriers regarding COVID-19 booster doses among dental patients in Lucknow, India, using a survey of 297 participants from dental clinics.
- Results show that only 37.7% received all three vaccine doses, while 57.9% received one or two doses, with a significant correlation between knowledge of boosters and vaccine uptake.
- Although only 18.2% expressed hesitation toward the booster dose, a majority recommended it to others, highlighting the need for healthcare professionals and policymakers to enhance awareness and vaccination efforts.
Article Abstract
Given the lingering threat of COVID infection, questions are being raised if coronavirus disease 2019 (COVID-19) vaccine needs annual or regular boosters to maintain high levels of immunity against both the original virus and variants. This study was designed to evaluate the knowledge, acceptance, motivators and barriers of the booster dose of COVID-19 vaccine among the dental patients of District Lucknow, India. A total of 297 respondents were selected by a convenience sampling method in this cross-sectional study from various dental clinics. An anonymous, self-administered, closed-ended questionnaire was used. Overall 37.7% respondents reported to have taken all 3 doses and 57.9% had taken single/double doses. Correct information about booster doses shows a significant association with the number of doses taken. The majority had information about the availability of the Pfizer booster vaccine (69.0%). About 58% of participants had information about the technology used in booster doses. The hesitancy for booster doses and the development of natural immunity by infection show significant associations with the number of doses taken. Only 18.2% patients had hesitation about the booster dose and most of them 78.8% recommended others to take the booster vaccine as soon as possible. The majority assumed that previous COVID-19 vaccines can help them get immune (21.5%) followed by not much research has been done on the booster vaccines (15.5%) and their chronic diseases warn them against the booster dose administration (12.5%). Nearly 18.2% of respondents had hesitation about booster dose and less than one third of the respondents trusted a government source for information about booster dose of COVID vaccine. Nearly 36 % did not know that the booster dose of COVID vaccine is available at health centers. Dental health professionals and policymakers should implement and support strategies to ensure people are vaccinated for COVID-19 booster doses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637537 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000035747 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.
Vaccine
January 2025
Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, the Gambia; Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Australia.
Introduction: Because booster doses of pneumococcal conjugate vaccine (PCV) may be given at a similar time to yellow fever vaccine (YF), it is important to assess the immune response to YF when co-administered with PCV. This has been investigated during a reduced-dose PCV trial in The Gambia.
Methods: In this phase 4, parallel-group, cluster-randomized trial, healthy infants aged 0-10 weeks were randomly allocated to receive either a two-dose schedule of PCV13 with a booster dose co-administered with YF vaccine at age 9 months (1 + 1 co-administration) or YF vaccine administered separately at age 10 months (1 + 1 separate) or the standard three early doses of PCV13 with YF vaccine at age 9 months (3 + 0 separate).
Circulating T cell subpopulations in dairy calves infected with Bovine viral diarrhea virus 2 and Bovine herpes virus 1 following modified-live virus booster vaccination: Effects of the administration route and trace mineral supplementation.
Vet Immunol Immunopathol
January 2025
Group for Reproduction in Animals, Vaccinology & Infectious Diseases (GRAVID™), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-2771, United States.
Article Synopsis
- The study aimed to assess how different routes of vaccine administration and the use of injectable trace minerals (ITM) affect immune responses in dairy calves infected with BVDV2 and BHV1.
- A total of 60 calves were vaccinated and monitored for immune cell counts, revealing that unvaccinated calves showed significantly lower leukocyte levels compared to vaccinated ones.
- Results indicated that calves receiving subcutaneous vaccinations had better immune response, particularly in CD4 T cells, and those in the ITM-IN group had the highest CD8 T cell counts, highlighting the importance of both the vaccination method and ITM usage in immune system effectiveness.
Patterns and Predictors of COVID-19 Vaccine Uptake Among U.S. Active Duty Service Members, 2020-2022: Implications for Future Pandemics.
Mil Med
January 2025
Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
Introduction: Vaccine mandates have been used to minimize the duty days lost and deaths attributable to infectious disease among active duty Service members (ADSMs). In response to the global COVID-19 pandemic, in August 2021, the U.S.
View Article and Find Full Text PDFSafety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain andN-Terminal Domain mRNA Vaccine.
J Infect Dis
January 2025
Moderna, Inc., Cambridge, MA 02142, USA.
Background: mRNA-1283 is an investigational COVID-19 mRNA vaccine encoding the receptor-binding and N-terminal domains of the SARS-CoV-2 spike protein in contrast to the original mRNA-1273, which encodes the full-length spike protein.
Methods: A phase 2a, dose-ranging, observer-blind, randomized study (NCT05137236) conducted in adults (≥18 years) previously vaccinated with mRNA-1273 evaluated the safety and immunogenicity of a single dose of mRNA-1283 (2.5, 5, and 10 µg) and its bivalent formulation, mRNA-1283.
Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
Vaccine
January 2025
Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway.
Background: The impact of vaccination on the type and risk of specific post-COVID symptoms after Omicron infection is not clear. We aimed to investigate the excess risk and patterns of 22 symptoms 3-5 months after Omicron infection, comparing uninfected and infected subjects with and without recent booster vaccination.
Methods: We conducted a population-based prospective study based on four questionnaire-based cohorts linked to national health registries.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!